HLA-C and cancer: The identification and choice of a neoantigen to be incorporated into an anti-cancer vaccine strategy obey several criteria, including the quality of the identification on a frozen tissue section, the link with the capture and restriction of major histocompatibility complex (MHC) molecules, the clonality of the mutation, the presentation of the epitopes, and the stability of the interaction between the mutant peptide and the MHC molecules; all of these criteria were included in an algorithmic prediction33.